Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma

Br J Haematol. 2019 Mar;184(6):1022-1025. doi: 10.1111/bjh.15212. Epub 2018 Apr 2.

Authors

Affiliations

¹ Università della Svizzera italiana (USI), Istituto Oncologico di Ricerca (IOR), Bellinzona, Switzerland.
² IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
³ Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
⁴ Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.

PMID: 29611184
DOI: 10.1111/bjh.15212

No abstract available

Keywords: BCL6; FLI1; chemotherapy; diffuse large B cell lymphoma; lymphomas.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use
Cell Line, Tumor
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics
Male
Middle Aged
Trabectedin / therapeutic use*
Transcription, Genetic / drug effects

Substances

Antineoplastic Agents
Trabectedin